PBAC's latest decision on Perindopril arginine with amlodipine besylate: Recommended with restriction (2010). Considered for Hypertension in a patient who is not adequately controlled with either of the drugs in the combination. Stable coronary heart disease in a patient who is stabilised on treatment with perindopril and amlodipine at the same doses.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
patients who are not adequately controlled with either of the drugs in the combination. Patients stabilised on treatment with perindopril and amlodipine at the same doses.
Therapy area
Cardiovascular
Evidence base
Bioequivalence studies, meta-analysis
Key trials
Stokes GS et al. Double-blind crossover study of the interaction between perindopril and amlodipine on blood pressure and hormones related to fluid and electrolyte balance in patients with essential hypertension.
Comparator
perindopril arginine and amlodipine besylate given concomitantly
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated